Nikolai Lorenzen
Overview
Explore the profile of Nikolai Lorenzen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
691
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Condado-Morales I, Dingfelder F, Waibel I, Turnbull O, Patel B, Cao Z, et al.
MAbs
. 2024 Oct;
16(1):2403156.
PMID: 39364796
Engineered antibody formats, such as antibody fragments and bispecifics, have the potential to offer improved therapeutic efficacy compared to traditional full-length monoclonal antibodies (mAbs). However, the translation of these non-natural...
2.
Herling T, Invernizzi G, Ausserwoger H, Rose Bjelke J, Egebjerg T, Lund S, et al.
Proc Natl Acad Sci U S A
. 2023 Dec;
120(52):e2306700120.
PMID: 38109540
Monoclonal antibodies (mAbs) have successfully been developed for the treatment of a wide range of diseases. The clinical success of mAbs does not solely rely on optimal potency and safety...
3.
Ausserwoger H, Schneider M, Herling T, Arosio P, Invernizzi G, Knowles T, et al.
Nat Rev Chem
. 2023 Apr;
6(12):844-861.
PMID: 37117703
Antibodies are highly potent therapeutic scaffolds with more than a hundred different products approved on the market. Successful development of antibody-based drugs requires a trade-off between high target specificity and...
4.
Rosace A, Bennett A, Oeller M, Mortensen M, Sakhnini L, Lorenzen N, et al.
Nat Commun
. 2023 Apr;
14(1):1937.
PMID: 37024501
Biologics, such as antibodies and enzymes, are crucial in research, biotechnology, diagnostics, and therapeutics. Often, biologics with suitable functionality are discovered, but their development is impeded by developability issues. Stability...
5.
Ausserwoger H, Krainer G, Welsh T, Thorsteinson N, de Csillery E, Sneideris T, et al.
Proc Natl Acad Sci U S A
. 2023 Apr;
120(15):e2210332120.
PMID: 37011217
Nonspecific interactions are a key challenge in the successful development of therapeutic antibodies. The tendency for nonspecific binding of antibodies is often difficult to reduce by rational design, and instead,...
6.
Erkamp N, Oeller M, Sneideris T, Ausserwoger H, Levin A, Welsh T, et al.
Anal Chem
. 2023 Mar;
95(12):5362-5368.
PMID: 36930285
Protein-based biologics are highly suitable for drug development as they exhibit low toxicity and high specificity for their targets. However, for therapeutic applications, biologics must often be formulated to elevated...
7.
Condado-Morales I, Sokolova V, Wahlund P, Heding K, Auclair S, Kingsbury J, et al.
Mol Pharm
. 2023 Jan;
20(2):1323-1330.
PMID: 36668814
Monoclonal antibodies (mAbs) are often formulated as high-protein-concentration solutions, which in some cases can exhibit physical stability issues such as high viscosity and opalescence. To ensure that mAb-based drugs can...
8.
Narayanan H, Dingfelder F, Morales I, Patel B, Heding K, Rose Bjelke J, et al.
Mol Pharm
. 2021 Sep;
18(10):3843-3853.
PMID: 34519511
In addition to activity, successful biological drugs must exhibit a series of suitable developability properties, which depend on both protein sequence and buffer composition. In the context of this high-dimensional...
9.
Dingfelder F, Henriksen A, Wahlund P, Arosio P, Lorenzen N
Methods Mol Biol
. 2021 Sep;
2313:241-258.
PMID: 34478142
In this method chapter, we provide a brief overview of the key methods available to measure self-association of monoclonal antibodies (mAbs) and explain for which experimental throughputs they are usually...
10.
Wolf Perez A, Lorenzen N, Vendruscolo M, Sormanni P
Methods Mol Biol
. 2021 Sep;
2313:57-113.
PMID: 34478132
Although antibodies have become the fastest-growing class of therapeutics on the market, it is still challenging to develop them for therapeutic applications, which often require these molecules to withstand stresses...